Positioning political selling, disclosed 2026-09-24
Options put/call open interest 1.19, read 2026-11-01
Ethical passes the values gate
Price253.62 USD
Fair value311.49
Ethical score83.7/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-10-24Read Markup232.65+9.0% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation228.69+10.9% to today ✓Markup gives way to Accumulation after a 5% rise in 6 weeks
2026-08-23Read Markup216.78+17.0% to today ✓Distribution gives way to Markup after a 5% rise in 4 weeks
2026-07-23Read Distribution205.99+23.1% to today Markup gives way to Distribution after a 5% rise in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Biogen holds its Markup at $253.62. The statistical read favours the sellers, held for 56 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 56 days
Price at the screen
$253.62
Valuation
109.79 trailing · 15.59 forward price to earnings
Values screen
PASS· score 83.7
Beta
0.09
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
22.34%
Below 33%
Interest-bearing debt is just 22.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.47%
Below 33%
Cash held in interest-bearing accounts and securities is 1.5% of assets, under the one-third limit.
Pass
Receivables
16.56%
Below 49%
Money owed to the company is 16.6% of assets, under the 49% limit.
Pass
Revenue purity
1.26%
Below 5%
Only 1.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Biogen clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 22%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BIIB's ethical verdict changes
Today BIIB passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OPPORTUNITY: it trades at roughly a 23% discount to our $311.49 fair value, narrow competitive moat, 10.60% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 22.8% margin of safety to the base estimate.
Third-party analyst targets: 32 covering, consensus Buy. The average target sits +4% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Old multiple sclerosis drugs at a discount
Think of Biogen as the firm still keeping the lights on for multiple sclerosis patients who rely on drugs such as Tysabri and Tecfidera. Those treatments keep delivering even as newer rivals arrive, and the shares sit at 205 with a forward multiple of just 12.5 times. Our fair value sits at 281, a 36 percent margin of safety, while revenue edges up 2 percent and margins hold at 14 percent. The ethical screen clears without issue.
The narrow moat and 8 percent return on equity explain why the market has not bid the stock higher. Yet the business still throws off cash from established therapies, and thirty analysts carry a buy rating with a 225 median target. That leaves room for the price to close toward our own number if execution stays steady.
Slow top line growth and a narrow moat remain real constraints. Any fresh competition or pricing pressure in the multiple sclerosis space could cap upside and leave the shares range bound. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BIIB trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$232.65+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$232.65+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$232.65+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$232.65+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup · changed$232.65+0.0%Entry 12
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$232.65+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$232.65+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$232.65+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$232.65+3.1%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219.
2026-10-13Accumulation$225.71-1.3%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
